Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has been effective vigilantly but unsuccessfully to produce an one off therapy, variously called Pro 140, leronlimab, as well as Vyrologix.

In development of this treatment, CytoDyn has cast its net wide and far both geographically and in terms of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be used is an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as a combination treatment in the treatment of multi-drug-resistant HIV are actually closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of my last few shares. My 1st CytoDyn post, “CytoDyn: What To Do When It is Too Good to be able to Be True?”, set away what follows prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan offered such a very marketing image in the Uptick Newswire interview which I came away with a bad impression of the business.

Irony of irony, my poor opinion of the business has grown steadily, although the disappointment hasn’t been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger at the moment still disappoints? Therein sits the story; allow me to explain.

CytoDyn acquired its much storied therapy (which I shall mean as leronlimab) returned throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor of the treatment as well as reduction of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti viral activity in HIV infected subjects. Today’s payment of $3.5 million transfers ownership of this technology and also connected intellectual property from Progenics to CytoDyn, and roughly twenty five million mg of bulk drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 million) along with the very first new drug program approval ($five million), and also royalty payments of five % of net sales after commercialization.

Since that point in time, CytoDyn’s leading nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to buy a sector cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with numerous therapies and numerous indications, it’s this single therapy as well as a “broad pipeline of indications” as it places it. I call some pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a potentially advantageous therapy in dozens of indications.

The opening banner of its on the site of its (below) shows an energetic company with diverse interests albeit centered on leronlimab, several illness sorts, multiple presentations in addition to multiple publications.

Could it all be smoke and mirrors? That’s a question I’ve been asking myself from the really start of the interest of mine in this particular business. Judging by the multiples of thousands of diverse responses on listings accessible via Seeking Alpha’s CytoDyn Summary page, I’m much from alone in this question.

CytoDyn is a classic battleground, or even some might say cult stock. Its adherents are fiercely shielding of the prospects of its, quick to label any bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *